Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rite Aid Decision On Return To PBM Sector Will Come In “Next Few Months”

This article was originally published in The Pink Sheet Daily

Executive Summary

Chain drug store company is putting together ideas for a PBM or pharmacy benefits administrator to allow 90-day retail prescriptions. Operation would also help Rite Aid “negotiate for rebates” to offset price competition against mail order.

You may also be interested in...



Rite Aid To Start PBM With Third-Party Vendor

Rite Aid is in negotiations with potential partners to establish a pharmacy benefit management subsidiary, CEO Sammons says. The PBM division would accommodate managed care plan mail order prescriptions with a third party providing claims adjudication and mail order services.

Rite Aid To Start PBM With Third-Party Vendor

Rite Aid is in negotiations with potential partners to establish a pharmacy benefit management subsidiary, CEO Sammons says. The PBM division would accommodate managed care plan mail order prescriptions with a third party providing claims adjudication and mail order services.

CVS' Retail Stores, PBM Will Be "Significant Participants" In Medicare – CEO

The pharmacy chain expects higher retail drug utilization under Medicare drug benefit due to employers dropping coverage for retirees who typically used mail-order pharmacies. The absence of mandatory mail provisions in the final Medicare Part D regulations is "good news," CVS says.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel